Psyence Biomedical (Psyence Biomedical) Change In Receivables : $-0.11 Mil (TTM As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Change In Receivables?

Psyence Biomedical's change in receivables for the quarter that ended in Mar. 2023 was $-0.11 Mil. It means Psyence Biomedical's Accounts Receivable increased by $0.11 Mil from Mar. 2022 to Mar. 2023 .

Psyence Biomedical's change in receivables for the fiscal year that ended in Mar. 2023 was $-0.11 Mil. It means Psyence Biomedical's Accounts Receivable increased by $0.11 Mil from Mar. 2022 to Mar. 2023 .

Psyence Biomedical's Accounts Receivable for the quarter that ended in Mar. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Psyence Biomedical's liquidation value for the six months ended in Mar. 2023 was $-0.46 Mil.

Psyence Biomedical Change In Receivables Historical Data

The historical data trend for Psyence Biomedical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Change In Receivables Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Change In Receivables

0.10

-0.11

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Change In Receivables	-	0.10	-0.11

Psyence Biomedical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.11 Mil.

Psyence Biomedical (NAS:PBM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Psyence Biomedical's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Psyence Biomedical's accounts receivable are only considered to be worth 75% of book value:

Psyence Biomedical's liquidation value for the quarter that ended in Mar. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.316	-	1.771	+	0.75 * 0	+	0.5 * 0
=	-0.46

Psyence Biomedical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024